Table 2.
Univariable analysis of outcomes.
| Variable | Distant Metastasis | Local/Distant Recurrence | Overall Survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 95% CI | 95% CI | 95% CI | ||||||||||
| HR | LL | UL | p-Value | HR | LL | UL | p-Value | HR | LL | UL | p-Value | |
| Diagnosis Age (continuous) | 1.02 | 0.96 | 1.09 | 0.5101 | 1.04 | 0.98 | 1.11 | 0.1952 | 1.04 | 0.98 | 1.11 | 0.2151 |
| Gender (male vs. female) | 2.07 | 0.46 | 9.27 | 0.3419 | 1.92 | 0.52 | 7.16 | 0.3315 | 3.20 | 0.76 | 13.52 | 0.1129 |
| AJCC Stage (III vs. I/II) | 24.26 | 4.17 | 141.15 | 0.0004 | 11.99 | 2.87 | 50.04 | 0.0007 | 7.64 | 1.25 | 46.83 | 0.0280 |
| Apical Thickness (continuous) | 1.30 | 1.08 | 1.57 | 0.0057 | 1.22 | 1.03 | 1.45 | 0.0203 | 1.15 | 0.95 | 1.39 | 0.1506 |
| LBD (continuous) | 1.49 | 1.15 | 1.94 | 0.0026 | 1.39 | 1.12 | 1.72 | 0.0026 | 1.21 | 0.97 | 1.50 | 0.0889 |
| COMS Size (large vs. small/medium) | 16.95 | 3.12 | 92.02 | 0.0010 | 7.97 | 2.07 | 30.71 | 0.0026 | 2.76 | 0.52 | 14.67 | 0.2329 |
| Primary Site (ciliary body vs. choroidal) | 2.54 | 0.31 | 21.13 | 0.3885 | 1.92 | 0.24 | 15.40 | 0.5377 | 0.00 | 0.00 | - | 0.9949 |
| Primary Therapy (enucleation vs. brachytherapy) | 7.59 | 0.91 | 63.34 | 0.0610 | 2.44 | 0.61 | 9.79 | 0.2076 | 9.16 | 1.12 | 74.58 | 0.0385 |